Altesa Biosciences has raised $75 million in Series B funding, which has been oversubscribed. The company was co-founded by Brett Giroir, a former US Deputy Secretary of Health. The funding will enable advances in antiviral treatment for chronic obstructive pulmonary disease (COPD). The treatment will advance to the middle stages of clinical trials. The goal is to transform the treatment of chronic lung diseases. The funding round was closed on February 19, 2026.[1]